Johnson & Johnson Innovation – JJDC was among the investors in an $11.7m round for blood sealant technology developer Gatt Technologies.

Netherlands-based surgical haemorrhage sealant developer Gatt Technologies closed a €10.5m ($11.7m) series B round yesterday featuring Johnson & Johnson Innovation – JJDC, the open innovation arm of healthcare products group Johnson & Johnson.

The round was led by a healthcare-focused investment entity called NGI and included government-founded regional development agency Oost NL. The company has not revealed details of earlier funding.

Founded in 2011, Gatt is developing synthetic blood sealants to control organ leakage and surgical bleeding more effectively than…